Eris Lifesciences reported a steady set of numbers for the third quarter, with profit and operating performance showing year-on-year growth.
The pharmaceutical company posted a 19% rise in net profit to ₹99.7 crore in Q3, compared to ₹83.7 crore in the corresponding quarter last year. The improvement in profitability reflects continued momentum in core operations.
Revenue for the quarter increased 10% year-on-year to ₹807 crore, up from ₹732 crore in the same period last year. The growth in revenue indicates sustained demand across the company’s key therapeutic segments.
Operating performance also remained firm during the quarter. EBITDA rose 11% to ₹282.3 crore from ₹254.7 crore a year ago. EBITDA margin improved slightly to 35%, compared with 34.8% in the year-ago quarter, reflecting stable operational efficiency.
The marginal expansion in margins, along with double-digit EBITDA growth, supported the overall increase in bottom-line performance.
